20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. outlines materials used in an August 5, 2026 investor webinar describing U.S. legislation creating the Multi-Cancer Early Detection Screening Coverage Act, which gives CMS authority to reimburse multi-cancer blood tests beginning in 2028. Management believes its OneTest multi-cancer assay could be positioned for Medicare reimbursement if it obtains FDA authorization and meets CMS clinical appropriateness criteria.
The presentation contrasts OneTest’s 12‑marker protein and inflammation panel, serial testing three times per year, and machine‑learning “velocity” algorithms with ctDNA approaches such as Grail’s Galleri, noting that Galleri’s randomized NHS‑Galleri trial of over 142,000 participants missed its primary endpoint and has a $949 list price. Exact Sciences’ Cologuard revenue ramp from $2M to $266M after Medicare coverage is used only as a contextual analogy.
Business updates include preliminary, unaudited indications that Q2 2026 produced the company’s best quarterly cancer testing revenue to date, 29 orders from new accounts, a Maryland firefighter screening program covering 18 departments and more than 1,400 participants, and selection for a Vermont program to screen up to 4,500 firefighters. The company describes a three‑month Giant Food pilot for its longevity test, a roll‑up M&A strategy targeting companies with $2–$8 million in annualized revenue, and hypothetical revenue projections that imply a 5% royalty pool of about $100 million over five years to be shared pro‑rata with “data investors,” all expressly conditioned on achieving regulatory and reimbursement milestones.
20/20 Biolabs, Inc. entered a standstill agreement with Streeterville Capital related to its previously arranged offering of up to $40,000,000 of Series E convertible preferred stock at $1,000 per share. For 120 days from July 16, 2026, Streeterville agrees not to convert Series E preferred shares into common stock unless the trading price is at least 10% greater than the Nasdaq “Minimum Price”, with the standstill ending upon any breach of the agreement or an Event of Default.
The company also received a Nasdaq notice of non-compliance with the $1.00 minimum bid price requirement after its shares closed below $1.00 for 30 consecutive business days from June 3, 2026 to July 16, 2026. 20/20 Biolabs has until January 13, 2027 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days, with the possibility of an additional 180-day period or eventual delisting if compliance is not restored.
20/20 Biolabs, Inc. used this report to share an investor presentation on its OneTest multi‑cancer early detection strategy, focused on potential future Medicare reimbursement. The company highlights the new Multi‑Cancer Early Detection Screening Coverage Act, which creates a pathway for Medicare coverage of multi‑cancer blood tests starting in 2028 for FDA‑authorized products deemed appropriate by CMS.
The presentation contrasts protein‑based OneTest with ctDNA competitors and describes a serial biomarker‑tracking model that uses 12 cancer and inflammation markers, velocity algorithms, and an anti‑inflammatory diet program. It cites modeled early‑stage sensitivity improvements with more frequent testing and real‑world data from over 35,000 U.S. firefighters by the end of 2026. Management also outlines an M&A strategy targeting health‑and‑wellness businesses with $2–$8 million in annual revenue and includes illustrative revenue projections and a 5% royalty pool for “data investors,” all explicitly labeled as hypothetical and contingent on obtaining FDA authorization and Medicare reimbursement.
20/20 Biolabs, Inc. is asking stockholders at its August 18, 2026 virtual annual meeting to elect six directors, ratify its auditor, approve a major charter change and adopt a new equity plan. Holders of 12,251,198 common shares as of June 22, 2026 can vote online, by phone, fax or mail.
The company seeks approval to amend its certificate of incorporation to increase authorized common stock from 50 million to 500 million shares and remove converted preferred stock series. It explains this is to ensure enough shares for potential conversions of series E preferred stock and future corporate purposes.
Stockholders are also asked to approve a 2026 Equity Incentive Plan covering 5,000,000 shares, with an automatic annual increase equal to 7% of shares outstanding, to grant options and other awards to employees, consultants and directors. The proxy also requests authority to adjourn the meeting if more time is needed to solicit votes and outlines standard governance practices, board independence and executive/director compensation.
20/20 Biolabs, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on August 18, 2026. Stockholders of record as of June 22, 2026 may vote on five proposals, including a Charter Amendment to increase authorized common stock from 50,000,000 to 500,000,000 shares and approval of a 2026 Equity Incentive Plan reserving 5,000,000 shares plus annual automatic increases equal to 7% of outstanding shares.
The proxy includes board and nominee information for six director seats, ratification of dbbmckennon as independent auditors, disclosure of audit fees for 2025 and 2024, executive compensation summaries, outstanding option schedules for named executives, and procedural voting details for virtual attendance, quorum rules and broker non-vote treatment.
20/20 Biolabs, Inc. reported that its Board of Directors approved an amendment to the company’s Amended and Restated Bylaws on May 19, 2026. The change lowers the shareholder quorum requirement for stockholder meetings from a majority of shares outstanding to one-third of shares outstanding.
This adjustment makes it easier for the company to reach a valid quorum and conduct official business at stockholder meetings, which can be important when investor participation is limited. The full text of Amendment No. 1 to the bylaws is filed as an exhibit to this report.
20/20 Biolabs, Inc. files a prospectus supplement to include its Form 10-Q and updates a resale registration for 10,105,000 shares of common stock for certain selling stockholders. The company reported cash and cash equivalents of $4,219,099, net loss of $2,174,836 for the three months ended March 31, 2026, and disclosed 5,000 shares of Series E convertible preferred stock outstanding.
The supplement references the company’s Nasdaq listing under the symbol AIDX and includes operating results showing decreased revenues to $353,375 for the quarter and working capital of $2,120,232. Management disclosed material weaknesses in internal controls and described remedial steps underway.
20/20 Biolabs, Inc. files a prospectus supplement registering 15,164,724 shares of common stock for resale by selling stockholders.
The filing incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, shows cash of $4,219,099 and a net loss of $2,174,836 for the three months then ended. Shares outstanding were 10,611,528 as of May 19, 2026.
20/20 Biolabs reported a significantly wider loss for the quarter ended March 31, 2026 as revenue declined. Revenue fell to $353,375 from $553,820, driven mainly by lower OneTest sales and continued BioCheck erosion after patent expiry.
Gross margin compressed to 17.8%, while sales, general and administrative expenses rose to $1.35 million, largely tied to Nasdaq direct listing costs. The company posted a net loss of $2.17 million, compared with $0.76 million a year earlier, and used $1.29 million in operating cash.
Liquidity improved through a private placement of series E convertible preferred stock providing $5.0 million of proceeds and $250,000 of new secured convertible notes, lifting cash to $4.22 million and working capital to $2.12 million. However, operations continue to rely on external financing, and management notes recent operating losses may persist. Material weaknesses in internal control over financial reporting remain, though remediation efforts are underway.
20/20 BioLabs reported first quarter 2026 results showing lower revenue and a wider loss but a much stronger cash position. Revenue for the three months ended March 31, 2026 was $353,375, down from $553,820 a year earlier, with gross margin at 17.8%.
Net loss widened to $2,174,836 from $764,577, reflecting higher sales, general and administrative costs tied to becoming a Nasdaq-listed public company, non-cash losses on convertible notes, and warrant remeasurement. Cash and cash equivalents increased to $4,219,099 from $1,025,987 at year-end, helped by a $5,000,000 Series E preferred stock private placement and new convertible notes.
The company highlighted state-funded firefighter cancer screening programs expected to drive revenue growth beginning in Q2 2026, a distribution agreement with Evexia Diagnostics, a CKD-focused license with ROKIT Healthcare, and the commercial launch of its OneTest™ for Longevity chronic disease risk test.